Randomized Trial of Apixaban vs Dose Adjusted Warfarin in Reducing Rate of Cognitive Function Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Non-valvular Atrial Fibrillation Patients With CHA2DS2-VaSc Score = 2
Latest Information Update: 19 Mar 2021
At a glance
- Drugs Apixaban (Primary) ; Warfarin (Primary)
- Indications Thromboembolism
- Focus Therapeutic Use
- Acronyms ARISTA
Most Recent Events
- 23 Feb 2021 Status changed from recruiting to discontinued due to slower than anticipated enrollment.
- 22 Feb 2019 New trial record